Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03552107|
Recruitment Status : Completed
First Posted : June 11, 2018
Last Update Posted : October 31, 2019
|Condition or disease||Intervention/treatment|
|Obesity Weight Loss Overweight||Drug: Lorcaserin|
|Study Type :||Observational|
|Actual Enrollment :||157 participants|
|Official Title:||Real World Experience With Lorcaserin for Weight Management|
|Actual Study Start Date :||April 11, 2017|
|Actual Primary Completion Date :||October 11, 2018|
|Actual Study Completion Date :||April 11, 2019|
Observational Group - Lorcaserin Treated
The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
Treatment initiation with Lorcaserin
Other Name: Belviq
- Weight change - in pounds [ Time Frame: Up to 1 year of medication use ]Change in weight with Lorcaserin treatment
- Duration of Use - in weeks [ Time Frame: Up to 1 year of medication use ]Average duration of treatment with Lorcaserin
- Change in heart rate [ Time Frame: Up to 1 year of medication use ]Assessment of change heart rate (bpm)
- Change in blood pressure [ Time Frame: Up to 1 year of medication use ]Assessment of change in both systolic and diastolic blood pressure (mmHg)
- Change in lipid levels [ Time Frame: Up to 1 year of medication use ]Assessment of change in lab values for total cholesterol, LDL, HDL and Triglycerides
- Change in liver enzymes [ Time Frame: Up to 1 year of medication use ]Assessment of change in lab values for AST and ALT
- Change in glucose values [ Time Frame: Up to 1 year of medication use ]Assessment of change in lab values for fasting glucose and hemoglobin A1c
- Reasons for Discontinuation [ Time Frame: Up to 1 year of medication use ]Reasons for discontinuing treatment with Lorcaserin - as obtained by annotation in patient's medical record from overseeing physician.
- Changes in Healthcare Utilization [ Time Frame: Up to 1 year of medication use ]Assessment of changes in healthcare utilization including all Scripps outpatient medical visits, visits to the ER and/or Urgent care, and inpatient hospitalizations. All of the above are assessed via the Scripps network EMR and only include visits made to a Scripps facility. Reason for visit and level of visit billed reviewed via EMR using billing and diagnosis codes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03552107
|United States, California|
|Scripps Whittier Diabetes Institute|
|San Diego, California, United States, 92121|
|Principal Investigator:||Ken Fujioka, MD||Scripps Clinic Medical Group|